Meeting
2021 ASCO Quality Care Symposium
Evaluation of direct oral anticoagulant use for cancer-associated venous thromboembolism (VTE) in lung cancer.
Authors
Leila Rostamnjad
Massachusetts General Hospital, Watertown, MA
Leila Rostamnjad, Ibiayi Dagogo-Jack
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Patient Experience; Quality, Safety, and Implementation Science; Technology and Innovation in Quality of Care
Track
Technology and Innovation in Quality of Care,Patient Experience,Quality, Safety, and Implementation Science,Cost, Value, and Policy,Health Care Access, Equity, and Disparities
Sub Track
Quality Improvement Research and Implementation Science
Citation
J Clin Oncol 39, 2021 (suppl 28; abstr 243)
DOI
10.1200/JCO.2020.39.28_suppl.243
Abstract #
243
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Gastrointestinal Cancers Symposium
An analysis of the efficacy and safety of direct oral anticoagulants (DOACs) in gastrointestinal cancer-associated venous thromboembolism (GI-CAVTE).
First Author: Alejandro Recio Boiles
Poster
2021 Genitourinary Cancers Symposium
A retrospective real-world major bleeding (MB) comparison of direct oral anticoagulants (DOAC) and low molecular weight heparin (LMWH) in genitourinary cancer-associated venous thromboembolism (GU-CAVTE) with reported randomized clinical trials (RTC).
First Author: Ulyana Dashkevych
Poster
2016 Gastrointestinal Cancers Symposium
Review of efficacy and safety of the new oral anticoagulants (NOACS) in the treatment of venous thromboembolism in gastrointestinal (GI) oncology patients.
First Author: Hitendra Patel
Poster
2017 ASCO Annual Meeting
Evaluation of an oral direct anti-Xa anticoagulant, apixaban, for the prevention of venous thromboembolism in patients with myeloma treated with IMiD* compounds: A pilot study (MYELAXAT).
First Author: Brigitte Pegourie